文献速递银屑病与炎症性皮肤病

比美吉珠单抗在中重度斑块状银屑病患者中从阿达木单抗、乌司奴单抗或司库奇尤单抗转换治疗后的疗效与安全性:III期/IIIb期试验结果

Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
PubMed 文献 · Br J Dermatol · 2023-01-01

本分析基于BE SURE、BE VIVID、BE BRIGHT和BE RADIANT试验,评估中重度斑块状银屑病患者从阿达木单抗、乌司奴单抗或司库奇尤单抗转换为比美吉珠单抗后的疗效与安全性,随访至转换后80周。结果显示,转换前未达PASI 90的患者中多数在转换后4周内即达PASI 90,且疗效持久;安全性良好,未发现新的安全性信号。

要点

  • 转换前未达PASI 90者中,转换后4周达PASI 90的比例分别为阿达木单抗67%、乌司奴单抗79%、司库奇尤单抗53%。
  • 比美吉珠单抗治疗48周后,上述三组未达PASI 90者中分别有91%、90%、79%达到PASI 90。
  • 转换前已达PASI 90者,转换后原有疗效维持或改善;安全性良好,未发现新信号。

核心结论

  • 对阿达木单抗、乌司奴单抗或司库奇尤单抗应答不充分的患者,转换为比美吉珠单抗后多数可获得高水平皮损清除。
  • 比美吉珠单抗耐受性良好,未发现新的安全性发现。

研究设计与样本

  • 报告BE SURE、BE VIVID、BE BRIGHT和BE RADIANT试验中患者转换为比美吉珠单抗后最长80周的数据。
  • BE SURE中第24周从阿达木单抗转换,BE VIVID中第52周从乌司奴单抗转换(进入BE BRIGHT开放标签扩展),BE RADIANT中第48周从司库奇尤单抗转换(进入BE RADIANT开放标签扩展)。
  • 疗效按转换后周数报告,并根据转换时是否达到PASI 90进行分组。
  • 治疗中出现的不良事件(TEAEs)以每100患者年的暴露调整发生率(EAIRs)报告。

主要发现

  • 转换前未达PASI 90者中,转换后4周达到PASI 90的比例:从阿达木单抗转换者为67%,从乌司奴单抗转换者为79%,从司库奇尤单抗转换者为53%。
  • 比美吉珠单抗治疗48周后,转换前未达PASI 90者中达到PASI 90的比例:从阿达木单抗转换者为91%,从乌司奴单抗转换者为90%,从司库奇尤单抗转换者为79%。
  • PASI 100、研究者总体评估(IGA)0/1、受累体表面积≤1%、绝对PASI≤2和皮肤病生活质量指数(DLQI)0/1也观察到持久改善。
  • 转换前已达PASI 90者,转换为比美吉珠单抗后原有治疗应答维持或改善。
  • 大多数TEAEs为轻度或中度;活性对照治疗期与转换为比美吉珠单抗后的EAIRs总体相似,且EAIRs通常随比美吉珠单抗暴露时间延长而下降。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Discontinuation of biologics is common among patients with psoriasis due to treatment failure or adverse events. To achieve improvements in disease management, patients and clinicians may choose to switch biologics. OBJECTIVES: To evaluate the efficacy and safety of switching to bimekizumab from adalimumab, ustekinumab and secukinumab. METHODS: Data are reported for up to 80 weeks after patients switched to bimekizumab from adalimumab at week 24 in BE SURE, ustekinumab at week 52 in BE VIVID [upon entry into the BE BRIGHT open-label extension (OLE)] and secukinumab at week 48 in BE RADIANT (upon entry into the BE RADIANT OLE). Efficacy outcomes are reported by number of weeks after switching to bimekizumab and were split based on whether patients had achieved a ≥ 90% improvement from baseline in Psoriasis Area and Severity Index (PASI 90) at the time of switch. Treatment-emergent adverse events (TEAEs) are reported using exposure-adjusted incidence rates (EAIRs) per 100 patient-years. Trial registration: BE SURE (NCT03412747), BE VIVID (NCT03370133), BE BRIGHT (NCT03598790), BE RADIANT (NCT03536884). RESULTS: Rapid and durable improvements in clinical responses and benefits in health-related quality of life were observed among PASI 90 nonresponders who switched to bimekizumab. Most PASI 90 nonresponders achieved PASI 90 4 weeks after switching to bimekizumab from adalimumab (67%), ustekinumab (79%) and secukinumab (53%). After 48 weeks of bimekizumab, 91%, 90% and 79% of PASI 90 nonresponders had achieved PASI 90 after switching from adalimumab, ustekinumab or secukinumab, respectively. Durable improvements were also observed for PASI 100, Investigator's Global Assessment score 0/1, body surface area affected by psoriasis ≤ 1%, absolute PASI ≤ 2, and Dermatology Life Quality Index 0/1. Among PASI 90 responders, existing treatment responses were maintained or improved after switching to bimekizumab. The majority of TEAEs were mild or moderate. EAIRs were generally similar between active-comparator treatment periods and after switching to bimekizumab. EAIRs typically decreased with a longer duration of bimekizumab exposure. CONCLUSIONS: High proportions of patients who did not adequately respond to adalimumab, ustekinumab or secukinumab achieved high levels of skin clearance after switching to bimekizumab. Bimekizumab was well tolerated and there were no new safety findings.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Kokolakis G, Warren RB, Strober B, et al. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. Br J Dermatol. 2023. PMID: 36751950. doi:10.1093/bjd/ljac089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。